CSIMarket Company Name, Ticker, Customers, else..
 
Profound Medical Corp   (NASDAQ: PROF)
 
Price: $6.8900 $0.09 1.324%
Day's High: $6.960000038146973 Week Perf: 1.32 %
Day's Low: $ 6.75 30 Day Perf: -13.22 %
Volume (M): 28,695 52 Wk High: $ 8.95
Volume (M$): $ 0 52 Wk Avg: $6.60
Open: $6.80 52 Wk Low: $3.76



 Market Capitalization (Millions $) 250
 Shares Outstanding (Millions) 36
 Employees 162
 Revenues (TTM) (Millions $) 19
 Net Income (TTM) (Millions $) 8
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a commercial-stage medical device firm that develops and markets AI-powered, MRI-guided, incision-free therapies for tissue ablation using platform technologies. Its lead product, the TULSA-PRO system, is designed for thermal ablation of prostate tissue in conditions including prostate cancer and benign prostatic hyperplasia. The Sonalleve system is used for ablation of uterine fibroids and other conditions. Both systems employ real-time MRI guidance and focused ultrasound energy to deliver customizable, incision-free ablative treatments.


   Company Address: 2400 Skymark Avenue, Unit #6, Mississauga 0 ON
   Company Phone Number: 476-1350   Stock Exchange / Ticker: NASDAQ PROF


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRC        6.14% 
BDX   -2.52%    
BSX        2.05% 
ISRG   -1.58%    
MDT        3.22% 
RMD   -4.98%    
• View Complete Report
   



Partnership

Bright Futures Copenhagen Infrastructure Partners and Norfund Forge Alliance for South African Renewable Energy

Published Thu, Nov 13 2025 1:14 PM UTC

In a significant stride towards bolstering renewable energy development in South Africa, the Copenhagen Infrastructure Partners (CIP) has entered into a strategic partnership with Norfund, the Norwegian Investment Fund for Developing Countries. The collaboration is set to channel USD 75 million into Mulilo, a prominent player in the South African renewable energy sector, mar...
Dividend

Profound Medical Achieves Spectacular Revenue Milestones and Secures $40 Million Offering: A Pioneering Force in Oncology Innovation,

Published Wed, Jan 8 2025 12:31 PM UTC

Profound Medical Reports Strong Revenue Growth for Q4 and Full Year 2024 Amidst Ongoing Innovations in OncologyProfound Medical, a leading entity in the field of medical technology focusing on the treatment of prostate cancer, has recently released preliminary unaudited revenues for the fourth quarter and the full year of 2024. This announcement highlights a remarkable year ...
Shares

“Profound Medical’s $40.25 Million Offering: Fueling Innovation in Oncology”,

Published Tue, Dec 10 2024 2:55 PM UTC

Profound Medical Secures $40.25 Million: A Strategic Move in Oncology InnovationIn a significant boost to its financial standing, Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) has announced the successful closing of its underwritten public offering, raising a total of US$40.25 million through the sale of common shares. The move not only enhances the company s liquidity bu...
Shares

Navigating Growth: Profound Medicals US$20M Public Offering Fortifies Future in Healthcare Innovation,

Published Thu, Dec 5 2024 9:48 PM UTC

Profound Medical Corp. Unveils US$20 Million Public Offering of Common Shares: Key Details and Insights on Funding StrategyIn a significant move to bolster its financial standing and drive future growth, Profound Medical Corp. (TSX:PRN; NASDAQ:PROF), a company at the forefront of healthcare innovation, has announced the pricing of its underwritten public offering of common s...
Product Service News

Profound Medical Presses Forward Unveiling Next-Gen TULSA-AI Module Amidst Competitive Market Landscape and Promis...

Published Tue, Nov 26 2024 12:45 PM UTC

In an era where innovation is paramount, Profound Medical continues to assert its presence in the medical technology sector with significant advancements and a focus on clinical efficacy. The company is gearing up to unveil its next TULSA-AI module, the UA Alignment Assistant, at the upcoming Radiological Society of North America (RSNA) and Society of Urologic Oncology (SUO)...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 1.96
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 13.29
Price to Sales (Expected) -
Price to Book 4.21
PEG (TTM) 0.13

Financial Strength Current
Quick Ratio 4.74
Working Capital Ratio 6.2
Leverage Ratio (MRQ) 0.31
Total Debt to Equity 0.15
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 3.52 $
Revenues (TTM) 0.52 $
Cash Flow (TTM) 0.07 $
Cash 1.39 $
Book Value 1.64 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 116,136
Net Income per Employee (TTM) 52,123
Receivable Turnover Ratio (TTM) 2.53
Inventory Turnover Ratio (TTM) 1
Asset Turnover Ratio (TTM) 0.31

Profitability Ratios Current
Gross Margin (MRQ) 71.8 %
Operating Margin (MRQ) -150.29 %
Net Margin (MRQ) -132.15 %
Net Cash Flow Margin (MRQ) -160.82 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 14 %
Return On Investment (TTM) 15.38 %
Return On Equity (TTM) 17.12 %
Dividend Yield -
Pay out Ratio (TTM) -



Profound Medical's Segments
Point in time revenue    96.35 % of total Revenue
Service revenue recognized over time    3.65 % of total Revenue
Recurring - non-capital    46.36 % of total Revenue
Capital equipment    53.64 % of total Revenue
Canada    66.91 % of total Revenue
Canada Recurring - non-capital    27.82 % of total Revenue
Canada Capital equipment    39.09 % of total Revenue
USA    30.28 % of total Revenue
USA Recurring - non-capital    15.72 % of total Revenue
USA Capital equipment    14.56 % of total Revenue
Germany    2.81 % of total Revenue
Germany Recurring - non-capital    2.81 % of total Revenue

  Profound Medical Outlook

On January 3 2024 the Profound Medical provided following guidance

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) announced its preliminary unaudited revenues for the fourth quarter and full year of 2023. As a leading medical device company, Profound specializes in the development and marketing of customizable, incision-free therapies for the ablation of diseased tissue. The company also provided an update on the commercialization progress of TULSA-PRO in the United States.

Due to the significant time gap between planned investment community meetings and the reporting of final 2023 results in March 2024, Profound chose to release this information. This will coincide with various investor events, including the 42nd Annual J.P. Morgan Healthcare Conference in San Fra...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.